文献速递乳腺癌

肿瘤浸润淋巴细胞与III期乳腺癌BRCA样状态及强化铂类化疗获益的关系

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
PubMed 文献 · Eur J Cancer · 2020-01-16

本研究基于1993至1999年一项III期乳腺癌随机对照试验,比较辅助强化铂类化疗与常规蒽环类化疗,评估248例HER2阴性肿瘤的间质TILs与BRCA样表型及预后关系。高TILs与三阴性乳腺癌和BRCA1样状态相关,校正临床特征后TILs与更优预后独立相关,但TILs与强化铂类化疗获益无显著交互作用。

要点

  • 高TILs与三阴性乳腺癌及BRCA1样状态相关。
  • BRCA样肿瘤TILs高于非BRCA样(中位20% vs 10%,p<0.01)。
  • TILs每增加10%,RFS和OS的多变量HR分别为0.82和0.80。

核心结论

  • 在高危III期乳腺癌队列中,高TILs与三阴性乳腺癌和BRCA1样状态相关。
  • 校正临床特征后,TILs与更有利的预后显著相关。
  • TILs与强化铂类化疗获益之间无显著交互作用。

研究设计与样本

  • 患者来自1993至1999年开展的III期乳腺癌辅助强化铂类化疗对比常规蒽环类化疗的随机对照试验。
  • 按国际指南对248例HER2阴性肿瘤的间质TILs进行评分。
  • 采用比较基因组杂交确定BRCA样表型。

主要发现

  • 高TILs与三阴性乳腺癌相关。
  • BRCA样肿瘤TILs高于非BRCA样肿瘤(中位20% vs 10%,p<0.01)。
  • BRCA1样肿瘤TILs高于BRCA2样肿瘤(中位20% vs 10%,p<0.001)。
  • 上述相关性在ER阳性亚组中仍显著,但在三阴性乳腺癌亚组中不显著。
  • TILs每增加10%,RFS多变量HR 0.82(95%CI 0.71-0.94,p=0.01),OS多变量HR 0.80(95%CI 0.68-0.94,p=0.01)。

关键数值与推荐

  • TILs按国际指南评分,对象为248例HER2阴性III期乳腺癌肿瘤。
  • BRCA样表型采用比较基因组杂交判定。
  • 高TILs与更优RFS和OS相关:每10%增量RFS HR 0.82(95%CI 0.71-0.94,p=0.01),OS HR 0.80(95%CI 0.68-0.94,p=0.01)。

临床怎么用

  • 在III期HER2阴性乳腺癌中可评估间质TILs以辅助预后判断。
  • TILs升高提示三阴性或BRCA1样表型可能,可结合BRCA样状态解读。
  • 现有数据不支持依据TILs选择强化铂类化疗。

局限性

  • TILs仅在248例HER2阴性肿瘤中评估。
  • BRCA样表型采用比较基因组杂交判定,非胚系BRCA1/2突变检测。
  • TILs与强化铂类化疗获益无显著交互作用,不能据此推荐化疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic value of tumour-infiltrating lymphocytes (TILs) differs by breast cancer (BC) subtype. The aim of this study was to evaluate TILs in stage III BC in the context of BRCA1/2-like phenotypes and association with outcome and benefit of intensified platinum-based chemotherapy. PATIENTS AND METHODS: Patients participated in a randomised controlled trial of adjuvant intensified platinum-based chemotherapy versus conventional anthracycline-based chemotherapy carried out between 1993 and 1999 in stage III BC. Stromal TILs were scored according to International guidelines in these human epidermal growth factor receptor 2 (HER2)-negative tumours. BRCA-profiles were determined using Comparative Genomic Hybridization. RESULTS: TIL levels were evaluated in 248 BCs. High TILs were associated with Triple Negative BC (TNBC). BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% versus 10%, p < 0.01). TIL levels in BRCA1-like tumours were higher compared to BRCA2-like tumours (median TILs of 20% versus 10%, p < 0.001). These correlations remained significant within the oestrogen (ER)-positive subgroup, however not within the TNBC subgroup. In this stage III BC cohort, high TIL level was associated with favourable outcome (TILs per 10% increment, recurrence-free survival (RFS): multivariate hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.71-0.94, p = 0.01; overall survival (OS): multivariate HR 0.80, 95% CI 0.68-0.94, p = 0.01). There was no significant interaction between TILs and benefit of intensified platinum-based chemotherapy. CONCLUSION: In this high-risk breast cancer cohort, high TILs were associated with TNBC and BRCA1-like status. Within the ER-positive subgroup, TIL levels were higher in BRCA1-like compared to BRCA2-like tumours. When adjusted for clinical characteristics, TILs were significantly associated with a more favourable outcome in stage III BC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. de Boo L, Cimino-Mathews A, Lubeck Y, et al. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. Eur J Cancer. 2020. PMID: 31956037. doi:10.1016/j.ejca.2019.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。